



A Schneeweiss

Contact

A Schneeweiss

Publications (14)

Loibl S, Staib P, Link T, Rhiem K, Solbach C, Fasching P, Nekljudova V, Denkert C, Untch M, Jackisch C, Thomalla J, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer J, Furlanetto J, Zahm D, Hanusch C, GBG and AGO-B. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. *Ann Oncol* 2022

Loibl S, Schmitt W, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching P, Weber K, Rhiem K, Denkert C, Jackisch C, Rezai M, Engels K, Untch M, Burchardi N, Huober J, Sinn B, Blohmer J, Grischke E, Furlanetto J, Tesch H, Hanusch C, Schneeweiss A. Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [*Annals of Oncology* (2019), volume 30:1279-1288]. *Ann Oncol* 2022; 33:743-744.

Müller V, Müller L, Janni W, Wimberger P, Jäger B, Pantel K, Riethdorf S, Harbeck N, Fehm T, Hoffmann O, Rübner M, Huober J, Banys-Paluchowski M, Friedl T, Fasching P, Schneeweiss A, Hartkopf A, Wallwiener D, Rack B, Meier-Stiegen F, DETECT study group. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. *ESMO Open* 2021; 6:100299.

Fasching P, Rhiem K, Schneeweiss A, Engels K, Denkert C, Schmutzler R, Hahnen E, Untch M, Burchardi N, Blohmer J, Loibl S, Doering G, Uleer C, Schmitt W, Link T, Hauke J, Seither F, Jackisch C, Klare P, Schmatloch S, Hanusch C, Huober J, Stefek A, Seiler S, German Breast Group and Arbeitsgemeinschaft Gynäkologische Onkologie Breast. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). *Ann Oncol* 2020; 32:49-57.

Karn T, Schmitt W, Wu S, van Mackelenbergh M, Müller V, Schem C, Stickeler E, Fasching P, Jackisch C, Untch M, Schneeweiss A, Marmé F, Blohmer J, Denkert C, Weber K, Holtrich U, Hanusch C, Sinn B, Higgs B, Jank P, Sinn H, Huober J, Becker C, Loibl S. Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. *Ann Oncol* 2020; 31:1216-1222.

Loibl S, Schmitt W, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching P, Weber K, Rhiem K, Denkert C, Jackisch C, Rezai M, Engels K, Untch M, Burchardi N, Huober J, Sinn B, Blohmer J, Grischke E, Furlanetto J, Tesch H, Hanusch C, Schneeweiss A. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. *Ann Oncol* 2019; 30:1279-1288.

Möbus V, Kurbacher C, Untch M, Konecny G, Hinke A, Runnebaum I, von Minckwitz G, Harbeck N, Huober J, Schneeweiss A, Nitz U, Kuhn W, Thomssen C, du Bois A, Lück H, Jackisch C, AGO Breast Study Group (AGO-B). Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial. *Ann Oncol* 2018; 29:178-185.

Möbus V, Thomssen C, Untch M, Nekljudova V, Loibl S, du Bois A, Bauerfeind I, Müller V, Huober J, Fehm T, Conrad B, Harbeck N, Elling D, Tesch H, Schneeweiss A, Lück H, Jackisch C, von Minckwitz G, German Breast Group (GBG), the AGO Breast Study Group (AGO-B) and NOGGO Study Groups. German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients. *Ann Oncol* 2017; 28:1803-1810.

von Minckwitz G, Jackisch C, Kümmel S, Fasching P, Schneeweiss A, Paepke S, Untch M, Burchardi N, Mehta K, Loibl S, Hanusch C, Denkert C, Rezai M, Tesch H, Huober J, Gerber B, Zahm D, Hilfrich J, Costa S, Dubsy P, Blohmer J, German Breast Group and Austrian Breast and Colon Cancer Study Group Investigators. Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-on (NaTaN) study (GBG 36/ABCSG 29). *Eur J Cancer* 2016; 64:12-21.

Untch M, Blohmer J, Costa S, Decker T, Diel I, Fasching P, Fehm T, Janni W, Lück H, Maass N, Scharl A, Beckmann M, Jackisch C, Thomssen C, Harbeck N, Huober J, von Minckwitz G, Gerber B, Kreipe H, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Loibl S. Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015). *Geburtshilfe Frauenheilkd* 2015; 75:556-565.

Schneeweiss A, Ruckhäberle E, Huober J. Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy?. *Geburtshilfe Frauenheilkd* 2015; 75:574-583.

von Minckwitz G, Costa S, Jackisch C, Paepke S, Schneeweiss A, Kümmel S, Denkert C, Mehta K, Loibl S, Blohmer J, Hanusch C, Rezai M, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Untch M. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro). *Ann Oncol* 2013; 25:81-9.

Schneeweiss A, Wallwiener D, Hamerla R, Solomayer E, Krauss K, Beldermann F, Rudlowski C, von Fournier D, Sinn H, Huober J, Bastert G. Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study. *European journal of cancer (Oxford, England : 1990)* 2004; 40:2432-8.

Huober J, Haas R, Bastert G, Goldschmidt H, Martin S, Meyer A, Wittmann G, Hohaus S, Schneeweiss A, Wallwiener D. Tandem and triple high-dose chemotherapy with autologous stem cell rescue in metastatic breast cancer. *Journal of cancer research and clinical oncology* 1998; 124:690-4.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch